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Background: The objective of this phase I trial was to determine 
dose-limiting toxicities (DLT) and the maximally tolerated dose 
of the radiosensitizer Nelfinavir in combination with concurrent 
chemoradiotherapy in locally advanced non-small cell lung cancer 
(NSCLC).
Methods: Nelfinavir (dose level 1: 625 mg orally [Po] twice a day; 
dose level 2: 1250 mg Po twice a day) was administered for 7 to 14 
days before and concurrently with concurrent chemoradiotherapy to 
patients with biopsy confirmed IIIA or IIIB unresectable NSCLC. 
Five patients were treated at dose level 1; eight patients were treated 
at dose level 2. Patients were treated with concurrent chemoradio-
therapy to a dose of 66.6 Gy. DLTs were defined as any treatment-
related grade 4 hematologic toxicity requiring a break in therapy or 
nonhematologic grade 3 or higher toxicity except esophagitis and 
pneumonitis.
Results: Sixteen patients were enrolled and 13 patients received at least 
one dose of nelfinavir. Twelve patients were treated with nelfinavir and 
concurrent chemoradiotherapy. No DLTs have been observed at either 
dose level. The maximum tolerated dose of nelfinavir was therefore 
1250 mg Po twice a day. Six patients experienced grade 4 leukopenia. 
one patient experienced grade 4 thromobcytopenia. Median follow-up 
for all 12 response-evaluable patients was 31.6 months and for sur-
vivors is 23.5 months. Nine of the 12 patients had evaluable post-
treatment positron emission tomography/computed tomography with 
metabolic response as follows: overall response: 9/9 (100%); complete 
response: 5/9 (56%); and partial response: 4/9 (44%).
Conclusion: Nelfinavir administered with concurrent chemora-
diotherapy is associated with acceptable toxicity in stage IIIA/IIIB 
NSCLC. The metabolic response and tumor response data suggest 
that nelfinavir has promising activity in this disease.
Key Words: Radiotherapy, Concurrent chemoradiotherapy, Locally 
advanced non-small cell lung cancer, Radiosensitizer.
(J Thorac Oncol. 2012;7: 709–715)
Approximately 50,000 patients are diagnosed annually with stage III non-small cell lung cancer (NSCLC). 
Five-year survival is extremely poor at 15 to 40%.1 A stan-
dard therapeutic approach for patients with unresectable 
stage IIIA disease is definitive radiotherapy to a dose of 60 
to 70 Gy given concurrently with a platin-based regimen.2 
one of the reasons for the poor cure rate in this disease is the 
inadequacy of local control with definitive radiotherapy. Le 
Chevalier et al.3 observed that the 1-year local control rate 
was ~17% for patients with unresectable NSCLC treated to 
65 Gy. A relationship has been shown between local fail-
ure and the subsequent appearance of distant metastases.4 
Furthermore, there is evidence to suggest an association 
between improved local control and better overall survival. 
In the CHART trial, hyperfractionated radiotherapy resulted 
in improved local control and survival.5,6 A similar correla-
tion between improved local control and survival was seen 
in the EoRTC study comparing concurrent chemoradiation 
versus radiation alone for locally advanced NSCLC. Two-
year local control improved from 19 to 31% with the addi-
tion of concurrent daily cisplatin. Two-year overall survival 
increased from 13 to 26% in the concurrent daily cisplatin 
arm.7 Therefore, an improvement in local control repre-
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sents a principal goal in designing new strategies to treat 
NSCLC.
one approach to improve local control with definitive 
radiotherapy is to deliver escalating doses to the tumor bed. 
Although this approach has been used, it comes at the cost of 
greater, and potentially fatal, toxicity to the patient.8,9 Another 
approach to improve the therapeutic ratio for tumor control is 
through concomitant administration of a radiosensitizing drug 
during standard dose radiotherapy.10,11 Preclinical studies have 
shown that a class of protease inhibitors used to treat HIV, 
radiosensitize tumor cells both in vitro and in vivo.12,13 The 
mechanism for this radiosensitization seems to be mediated, 
in part, through inhibition of P-I-3 kinase.12
Nelfinavir is a selective, nonpeptidic, inhibitor that binds 
with high affinity to the active site of the HIV protease. The 
most common side effects of this drug is diarrhea occurring 
in ~30% of patients.14 This is controlled with over-the-counter 
antidiarrheals and usually is mild to moderate in nature not 
resulting in weight loss. Hyperglycemia and hyperlipidemia 
has been reported with prolonged use of all of the HIV pro-
tease inhibitors. Additionally, elevation of liver enzymes has 
been reported in HIV patients with hepatitis B and C infection 
as a result of immune reconstitution with elevation of the CD4 
counts.15 The standard dosing regimen for nelfinavir is 1250 
mg given twice daily. This regimen was proven to be effective 
in a phase III randomized trial (AG-542) comparing dosing 
regimens of nelfinavir in HIV patients.14 In vitro and in vivo 
studies confirm that AKT phosporylation by P-I-3 kinase is 
inhibited by nelfinavir when given at the serum concentrations 
that are routinely achieved with the standard HIV dosing regi-
men of 1250 mg twice daily.12
on the basis of these preclinical data, our group initi-
ated a phase I trial of the HIV protease inhibitor nelfinavir with 
concurrent chemoradiotherapy for unresectable stage IIIA/IIIB 
NSCLC. The primary objective of this study was to determine 
the dose-limiting toxicities (DLTs) and the maximally tolerated 
dose of nelfinavir when administered with concurrent chemo-
radiotherapy. Response to therapy was assessed by positron 
emission tomography (PET) and computed tomography (CT).
MATERIALS AND METHODS
Eligibility
Patients aged 18 to 89 years with histologically proven 
NSCLC were enrolled onto this prospective trial. Patients 
had to be deemed unresectable by the thoracic oncology team 
at the University of Pennsylvania and planned for defini-
tive chemoradiotherapy. Patients were required to have an 
Eastern Cooperative oncology Group performance status of 
0 to 2 and not more than 10% unintended weight loss in the 6 
months before enrollment. Patients were required to have suf-
ficient hematologic and renal function to permit cisplatinum-
based chemotherapy. Patients who had received prior thoracic 
radiotherapy were excluded. With long-term use of nelfinavir 
(3 years), there are reports of exacerbation of hyperglyce-
mia in patients with type 2 diabetes.16 This trial mandates a 
short course (8 week) of nelfinavir, therefore patients with 
type 2 diabetes were not excluded. As mentioned previously, 
the liver enzyme elevation in patients with hepatitis B or C 
receiving nelfinavir is believed to be due to immune recon-
stitution in HIV infected individuals and not drug effect.15 
Patients with history of HIV infection were excluded from this 
trial, however, patients with hepatitis B or C in the absence 
of HIV infection were not excluded. The Institutional Review 
Board at the University of Pennsylvania approved this study. 
All patients signed informed consent.
Trial Design
All subjects began taking daily oral nelfinavir (either 
625 mg orally [Po] twice a day or 1250 mg Po twice a day) 7 
to 14 days before the start of chemoradiotherapy. In preclinical 
studies, there was evidence of inhibition of Akt phosphoryla-
tion after 3 days of nelfinavir with no detectable phosphory-
lated Akt by immunoblot at the serum concentrations that are 
achieved with the dosing regimens that range from 625 to 
1250 mg Po twice a day. Therefore, our starting dose level 
for this study was 625 mg Po twice a day with a top dose 
level of 1250 mg Po twice a day.12 A 7- to 14-day interval was 
chosen to ensure inhibition of Akt phosphorylation before ini-
tiation of chemoradiotherapy. Nelfinavir was continued at the 
prescribed dose level (either 625 mg Po twice a day or 1250 
mg Po twice a day) during the complete course of concurrent 
chemoradiotherapy and discontinued on the last day of radio-
therapy (Figure 1). All patients underwent CT-based treatment 
planning. All fields were treated every session. The gross 
tumor volume, clinical target volume, and planning target vol-
ume are defined according to ICRU 50. Elective irradiation of 
regional lymph nodes was allowed. All patients were treated 
using involved field technique to 66.6 Gy in 1.8 Gy/fraction. 
Normal tissue doses: the maximal spinal cord dose was lim-
ited to 45 Gy. No more than 30% of the total lung volume 
received greater than 20 Gy. No more than 50% of the total 
cardiac volume received greater than 40 Gy. To account for 
respiratory excursion, a four-dimensional CT was performed 
and an internal target volume generated. Before availability of 
a four-dimensional CT, patients with lower lobe tumors under-
went fluoroscopy and a margin was generated based on dia-
phragmatic excursion. Upper lobe tumors were treated with 
an empiric 1.2 cm three dimensionally expanded margin to 
the clinical target volume to account for both set-up variance 
and tumor excursion.
Standard chemotherapy consisting of cisplatinum and 
etoposide was administered as concurrent therapy with radia-
tion in accordance with the standard Southwest oncology 
Group regimen.17,18 Cisplatinum 50 mg/m2 was administered 
on days 1, 8, 29, and 36, with pretreatment and posttreatment 
hydration and a polyantiemetic regimen. Etoposide 50 mg/m2 
was administered days 1 to 5 and 29 to 33.
Toxicity and Response Assessment
DLTs were defined as any treatment-related grade 
4 hematologic toxicity requiring a break in therapy for 
greater than 14 days or nonhematologic grade 3 or higher 
toxicity except esophagitis and pneumonitis. This defini-
tion of DLT was chosen as treatment breaks in chemother-
apy commonly occur because of hematologic toxicity in 
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patients receiving concurrent chemoradiotherapy for locally 
advanced NSCLC.19 Given the anticipated rate of grade 3 
esophagitis of up to 50% and grade 3 pneumonitis of up to 
30% in patients receiving concurrent chemoradiotherapy 
alone, these were not considered to be DLTs for nelfinavir 
in this trial.20 Nelfinavir dose was escalated using a standard 
3 + 3 design with allowance for accrual of an additional three 
patients at the maximally tolerated dose. All patients under-
went either a CT of the chest (12/12) and/or a PET/CT (9/12) 
3 months after completion of treatment for assessment of 
response. All PET/CT scans were reviewed by an independent 
nuclear medicine physician (DP) and metabolic response was 
determined as previously described by Kong et al.21 All CT 
scans were scored by the RECIST criteria by an independent 
radiologist (M.A.R.). Local failure was defined as radiographic 
evidence of relapse within the primary tumor. Regional fail-
ure was defined as radiographic evidence of relapse within 
the regional hilar, mediastinal, or supraclavicular nodes. 
Distant failure was defined as failure in a nonregional nodal 
or extrathoracic site.
RESULTS
Patient Characteristics
A total of 16 patients with biopsy proven stage IIIA or 
IIIB NSCLC were enrolled from June 2007 to January 2009, 
of which 13 received at least one dose of nelfinavir. Three 
patients were found to have metastatic disease and therefore 
ruled ineligible before initiation of nelfinavir. As stated above, 
all 13 patients were followed for acute toxicity and 12 patients 
who received nelfinavir and initiated concurrent chemoradio-
therapy were assessed for response to therapy. The patient 
characteristics of the 12 response-evaluable patients followed 
for response assessment are given in Table 1. The mean age 
was 59 years and 58.3% were males. The majority (58.3%) 
of the patients had stage IIIB disease. T stage was T1/T2 in 
16.6%, T3 in 50%, and T4 in 33.3%. N stage was N2 in 75% 
and N3 in 25%. Performance status was 80 or greater (80–90). 
Histology was adenocarcinoma in 42%, squamous cell in 
42%, and poorly differentiated in 16%.
FIGURE 1. Study design.
TABLE 1. Patient Characteristics
 No. Percentage
All patients 12 100.0
Age Median, 59 Range (54–75)
Gender
 M 7 58.3
 F 5 41.7
Stage
 IIIA 5 41.7
 IIIB 7 58.3
T stage
 T1 1 8.3
 T2 1 8.3
 T3 6 50.0
 T4 4 33.3
N stage
 N0–N1 0 0.0
 N2 9 75.0
 N3 3 25.0
Karnofsky PS score
 80 7 58
 90 5 42
Histology   
 Adenocarcinoma 5 42
 Squamous cell 5 42
 Poorly differentiated 2 16
Clinical and pathological characteristics of 12 patients who received nelfinavir and 
concurrent chemoradiotherapy for locally advanced non-small cell lung cancer and were 
evaluable for response.
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Dose Escalation
A total of five patients were accrued to dose level 1 
(625 mg Po twice a day, dose level 1). The final two patients 
in the dose cohort should have been escalated to 1250 mg 
twice a day but were identified to have inadvertently taken 
the dose level 1 dose at the time of initial pill diary audit 
(14 days after initiation of drug). After discussion with the 
Abramson Cancer Center’s Clinical Trial Scientific Review and 
Monitoring Committee, it was decided that these two patients 
should continue at the lower dose level. A total of eight patients 
were accrued to dose level 2 (1250 mg Po twice a day; dose 
level 2). one patient withdrew after 2 days of nelfinavir ther-
apy before initiation of chemoradiotherapy. This patient is fol-
lowed for toxicity only. one patient discontinued because of 
anxiety (not drug related) after 19 days of nelfinavir (1980 
cGy radiation dose). Therefore, although eight patients were 
TABLE 2. Toxicity Data for All 13 Patients Enrolled on Trial 
of Nelfinavir and Concurrent Chemoradiotherapy for Locally 
Advanced Non-small Cell Lung Cancer and Evaluable for 
Toxicity
Toxicity Grade 0–2 Grade 3 Grade 4
Leukopenia 4 3 6
 Dose level 1 2 1 2
 Dose level 2 2 2 4
Anemia 11 2 0
 Dose level 1 5 0 0
 Dose level 2 6 2 0
Thrombocytopenia 10 2 1
 Dose level 1 4 0 1
 Dose level 2 6 2 0
Upper gastrointestinal 10 3 0
 Dose level 1 4 1 0
 Dose level 2 6 2 0
Lower gastrointestinal 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
Esophagitis 9 4 0
 Dose level 1 4 1 0
 Dose level 2 5 3 0
Pulmonary 12 1 0
 Dose level 1 5 0 0
 Dose level 2 7 1 0
Pericarditis 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
Hemoptysis 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
Hypotension 12 1 0
 Dose level 1 5 0 0
 Dose level 2 7 1 0
Hiccoughs 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
Skin 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
Fatigue 11 2 0
 Dose level 1 5 0 0
 Dose level 2 6 2 0
Headache 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
DVT 12 1 0
 Dose level 1 5 0 0
 Dose level 2 7 1 0
Dysuria 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
Alkaline phosphatase 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
TABLE 2. (Continued )
Toxicity Grade 0–2 Grade 3 Grade 4
Creatinine 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
Hyperbilirubinemia 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
Hyperglycemia 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
Hypercalcemia 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
Hyperkalemia 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
Hypoalbuminemia 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
Hypocalcemia 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
Hypoglycemia 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
Hypokalemia 12 1 0
 Dose level 1 5 0 0
 Dose level 2 7 1 0
Hypomagnesemia 11 2 0
 Dose level 1 4 1 0
 Dose level 2 7 1 0
Hyponatremia 11 2 0
 Dose level 1 3 2 0
 Dose level 2 8 0 0
Transaminases 13 0 0
 Dose level 1 5 0 0
 Dose level 2 8 0 0
Dose Level 1:5 Patients, Dose Level 2: 8 Patients, Total: 13 Patients Enrolled.
Continued
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accrued to dose level 2, only seven were followed for response 
assessment. All eight were followed for toxicity.
Toxicities
The toxicities associated with each dose level of nel-
finavir are given in Table 2. There were no DLTs. The rate 
of grade 3 or 4 toxicities appeared similar for the two dose 
levels. Two patients initiated nelfinavir with concurrent 
chemoradiotherapy and then withdrew from the study: one 
patient withdrew as a result of anxiety (not drug related) as 
noted above and a second patient withdrew after 5 weeks 
of concurrent chemoradiotherapy with nelfinavir because 
of treatment-related grade 3 esophagitis. All other patients 
completed nelfinavir with concurrent chemoradiotherapy as 
per protocol, with no delays in radiotherapy.
Hematologic Toxicities
The primary grade 3 or 4 hematologic toxicity observed 
was leukopenia. Three patients at dose level 1 (60%) and six 
patients at dose level 2 (75%) experienced grade 3 or 4 leuko-
penia. No patients required dose attenuation of chemotherapy 
or nelfinavir.
Nonhematologic Toxicities
There were no nonhematologic grade 4 toxicities. The 
primary nonhematologic grade 3 toxicity was esophagitis 
experienced by three patients at dose level 2 (37.5%) and one 
patient at dose level 1 (20%). one patient at dose level 2 with-
drew because of difficulty with pill swallowing secondary to 
esophagitis after 5 weeks. He was admitted with a complaint of 
difficulty swallowing, nausea, and fatigue (all scored as grade 
3) and discontinued nelfinavir during the hospitalization. one 
patient at dose level 2 had grade 3 esophagitis and orthostatic 
hypotension requiring home IV fluids for 2 weeks after com-
pletion of chemoradiotherapy. This was felt to be attributable 
to chemoradiotherapy and not thought to be a nelfinavir-re-
lated toxicity. one patient at dose level 2 developed grade 3 
pulmonary toxicity (dyspnea) requiring hospital admission 
for one night. This occurred before initiation of chemoradio-
therapy while the patient was on nelfinavir. A CT of the chest 
was obtained to rule out pulmonary embolism. No disease 
progression was evident on this scan. The patient was given 
nebulizers overnight and discharged the following morning. 
Her dyspnea resolved without any further intervention.
one patient at dose level 2 developed a grade 3 deep 
venous thrombosis (DVT) requiring hospitalization 1 month 
after discontinuation of nelfinavir and withdrawal from the 
study as a result of anxiety. The patient was admitted and initi-
ated on anticoagulation. The DVT was not felt to be related 
to study drug. This patient also experienced grade 3 fatigue 2 
weeks after withdrawal from the study because of anxiety. She 
reported fatigue severe enough to interfere with her activities 
of daily living. The rate of grade 3 or 4 nonhematologic toxici-
ties appeared to be similar between the two dose levels.
The overall rate of pill compliance on study ranged 
from 65 to 100% with a median pill compliance rate of 98%. 
Pill compliance rate appeared to be comparable for the two 
dose levels.
Response and Follow-Up
Table 3 shows the clinical outcome of all 12 patients fol-
lowed for response. Four patients achieved a complete response 
(CR) and seven patients achieved a partial response (PR). 
Nine of the 12 patients underwent a PET/CT at 3 months after 
completion of therapy. Five of the nine patients experienced a 
metabolic CR within the radiation field (locoregional CR) and 
the remaining four had a PR with at least a 30% reduction in 
standardized uptake value (Figure 2). one patient experienced 
local progression at 9 months after study entry identified on 
a routine follow-up CT scan, which also documented distant 
TABLE 3. Response and Clinical Outcome of 12 Patients Who Received Nelfinavir and Concurrent Chemoradiotherapy for 
Locally Advanced NSCLC and Were Evaluable for Response
Patient
TNM 
Stage
PET  
Response
Best Target Lesion 
CT Response 
(RECIST)
Local  
Control Status Disease Status
Survival 
(mo)
1 T3N3 CR PR Controlled at death Dead with distant disease 13
2 T4N2 PR PR Controlled in RT field Alive without disease 36+
3 T3N3 PR CR Controlled in RT field Alive without disease 35+
4 T2N3 PR SD Controlled at death Dead with distant disease 6
5 T1N2 CR CR Controlled in RT field Alive without disease 32+
6 T4N2 N/A PR Local Progression Dead with distant disease 22
7 T3N2 PR PR Controlled at death Dead without disease 7
8 T4N2 CR PR Controlled in RT field Alive without disease 24+
9 T3N2 CR PR Controlled in RT field Alive with controlled disease not 
receiving therapy at present
23+
10 T4N2 N/A CR Controlled at death Dead with distant disease 19
11 T3N2 CR PR Controlled in RT field Alive with controlled disease not 
receiving therapy at present
22+
12 T3N2 N/A CR Controlled at death Dead with distant disease 8
NSCLC, non-small cell lung cancer; TNM, tumor nodal metastasis; PET, positron emission tomography; CT, computed tomography; RT, radiotherapy; CR, complete response; 
PR, partial response; SD, stable disease.
714 Copyright © 2012 by the International Association for the Study of Lung Cancer
Rengan et al. Journal of Thoracic Oncology  •  Volume 7, Number 4, April 2012
progression. All other patients are locally controlled and alive 
or were locally controlled at the time of death.
Seven patients experienced distant disease progres-
sion. Five of the seven patients have died of distant disease. 
Two patients recurred distantly and have completed salvage 
therapy and are under follow-up. In one patient, a biopsy con-
firmed metastases in the adrenal gland and cervical lymph 
node. The patient was treated with salvage focal radiotherapy 
to both of these sites and is currently controlled 9 months 
after receiving salvage therapy. In another patient, a biopsy 
confirmed supraclavicular nodal metastasis 13 months after 
study entry and received concurrent chemoradiotherapy as 
salvage treatment. The patient was subsequently identified to 
have a contralateral fluorodeoxyglucose-avid pulmonary nodule, 
which was not amenable to biopsy 19 months after study entry. 
The case was reviewed in the multidisciplinary tumor board 
and felt to be consistent with recurrence. The patient received 
salvage stereotactic body radiation therapy to this contralateral 
nodule. He remains controlled 7 months after stereotactic body 
radiation therapy without any further therapy. There are four 
patients who are alive without evidence of disease. Two patients 
had only a partial response on CT and as a result both under-
went biopsy. one patient had a mediastinal nodal biopsy, which 
was negative for malignancy and revealed lymphocytes only. 
The second patient underwent biopsy of a residual parenchymal 
lung mass that confirmed fibrosis. Eleven of twelve patients had 
a best response of at least a partial response with four complete 
responders on CT by RECIST criteria (Figure 3).
DISCUSSION
This study reports the safety and feasibility of nelfinavir 
administration with concurrent chemoradiotherapy in patients 
with unresectable locally advanced NSCLC. Activation of 
signal transduction pathways has been shown to be a cause 
of intrinsic radiation resistance with much work focusing on 
EGFR, Ras, and Akt. our group has demonstrated that p-Akt 
is a marker for cells that are relatively resistant to radiother-
apy. We have also shown that nelfinavir, a protease inhibitor 
used in the treatment of HIV inhibits PI3K/AKT signaling and 
sensitizes tumor cells to killing by ionizing radiation in vitro 
and in vivo.12 Interestingly, we found that the radiosensitiz-
ing effect of nelfinavir and other inhibitors that downregulate 
PI3K/AKT signaling is greater in vivo than would be pre-
dicted on the basis of the in vitro clonogenic survival assays.12 
We therefore examined factors that might play a role in the in 
vivo radiation response and found that nelfinavir administra-
tion downregulates vascular endothelial growth factor signal-
ing and improves tumor oxygenation. We, and others, have 
also demonstrated that nelfinavir in animal models improves 
tumor perfusion suggesting that the observed enhancement of 
tumor oxygenation is due to increased blood flow to the tumor 
bed22; whether this represents an important mechanism of 
radiosensitization is not established, but we hypothesize that it 
is. Clearly, favorable modulation of the tumor microenviron-
ment is not the only mechanism of radiosensitization because 
of the radiosensitization observed in vitro. These observations 
led to our hypothesis that nelfinavir and other agents such as 
gefitinib inhibit critical intracellular signaling pathways and 
alter the tumor microenvironment leading to decreased vascu-
lar permeability and vascular normalization, improved tumor 
perfusion, and increased oxygenation. Therefore, unlike tar-
geted vascular endothelial growth factor inhibitors, nelfinavir 
can potentially address both intrinsic and extrinsic mecha-
nisms of radiation resistance.
on the basis of these preclinical data, we initiated a 
phase I clinical trial of nelfinavir with concurrent chemora-
diotherapy for patients with locally advanced NSCLC. Two 
dose levels were tested in this study: 625 mg Po twice a day 
and 1250 mg Po twice a day. Both dose levels were well tol-
erated. Although no DLT was observed, escalation did not 
continue past the recommended dose of nelfinavir used in 
HIV therapy.
our data suggest that nelfinavir may have activity in 
NSCLC. The locoregional metabolic response rate was 100% 
with five of nine patients (56%) having a CR on PET/CT 
obtained 3 months after completion of treatment. Although 
these results compare favorably with the 73% partial meta-
bolic response and 23% complete metabolic response rate 
FIGURE 2. Example of pretreatment and posttreatment 
positron emission tomography (PET)/computed tomography 
(CT) scan showing a complete metabolic response to chemo-
radiotherapy and nelfinavir.
FIGURE 3. Waterfall plot of best response by RECIST of all 
12 response-evaluable patients receiving concurrent chemo-
radiotherapy and nelfinavir.
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on PET in this population in previously published studies,21 
it is important to note that the conclusions that can be drawn 
from the response data in our study are limited by the small 
patient numbers and potential for patient selection bias.
These data suggest that nelfinavir may achieve radio-
sensitization in NSCLC. Brunner et al.23 recently published 
their experience with nelfinavir and concurrent chemoradio-
therapy in locally advanced pancreatic cancer with similar 
response rates. of 12 patients with borderline resectable/
unresectable pancreatic cancer, six were able to undergo 
surgical resection after chemoradiotherapy with nelfinavir. 
one patient had a pathologic CR to therapy. Interestingly, 
they also observed a higher rate of response on PET than 
on CT as this study. This suggests that PET may provide 
better discrimination of residual disease from fibrosis after 
radiotherapy.
There is emerging data on antineoplastic therapy in HIV 
patients who are being treated with HIV protease inhibitors.24 
Nelfinavir is an inducer of CYP3A4 and etoposide is metab-
olized by this enzyme, therefore there is the potential for a 
drug interaction. There are conflicting data that whether this 
interaction would result in potential antagonism or enhance-
ment of etoposide by nelfinavir as the CYP3A4 metabolites 
of etoposide have cytotoxic effect.25 At present, although data 
were limited, there is no evidence of enhancement of grade 4 
toxicities in trials of HIV patients receiving etoposide while 
on nelfinavir.26,27 Therefore, the standard platform of platinum 
etoposide was used in this phase I trial. However, it should be 
noted that because of the small patient numbers in this study, 
it is not possible determine whether nelfinavir had either an 
antagonistic or enhancing effect on the actions of etoposide in 
our patient population.
Because there were no DLTs observed in this trial, the 
recommended phase II dose of nelfinavir with concurrent 
chemoradiotherapy was determined to be 1250 mg Po twice 
a day. The predominant pattern of failure was distant disease, 
with only one patient experiencing local progression in this 
study. This underscores the importance of improving systemic 
treatment approaches in this disease. Based on the promising 
response rate and local control observed in this study, we are 
moving forward with a phase II trial.
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